Cerevel Therapeutics Holdings, Inc. (CERE)
NASDAQ (CM) NASDAQ (CM) Primary 
CEREVEL INVESTOR NOTICE: Cerevel's (NYSE:CERE) $45 Per Share Offer is Being Investigated by BFA Law, Shareholders are Reminded to Contact the Firm
NEW YORK, NY / ACCESSWIRE / June 21, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
CERE Shareholders Can Participate In The Cerevel Therapeutics Holdings Inc Probe Led By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
CEREVEL SHAREHOLDER ALERT: Is $45 Per Share Enough for Cerevel (NYSE:CERE)? Contact BFA Law about its Ongoing Review into the Offer
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
Shareholders Of CERE Have The Opportunity To Be Involved In The Investigation Of Cerevel Therapeutics Holdings Inc Directed By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
CEREVEL INVESTIGATION REMINDER: Think $45 Per Share is Too Low for Cerevel (NYSE:CERE)? Contact BFA Law about Ongoing Investigation into the Offer
NEW YORK, NY / ACCESSWIRE / June 19, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
Investors Of CERE Can Participate In The Probe Of Cerevel Therapeutics Holdings Inc Led By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
CEREVEL STOCK INQUIRY: Is $45 Per Share Enough for Cerevel (CERE)? Contact BFA Law about Ongoing Investigation into the Deal Price
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
CEREVEL NOTIFICATION: Think $45 Per Share is Too Low for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoing Investigation into the Acquisition Price
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
CEREVEL INVESTOR ALERT: Think $45 Per Share is Too Low for Cerevel (Nasdaq:CERE)? BFA Law Reminds You to Contact the Firm about Ongoing Investigation into the Deal Price
Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
BFA Law Notice: Cerevel (Nasdaq:CERE) Shareholders are Encouraged to Contact the Firm about Investigation into Whether the $45 Per Share Offer is Enough
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cere.
CEREVEL MERGER NEWS: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Reminds Investors to Contact the Firm About Your Rights
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
